Biofrontera Inc reports results for the quarter ended March 31 - Earnings Summary

• Biofrontera Inc BFRI.OQ reported a quarterly adjusted loss of 47 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-2.88. The mean expectation of two analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -29 cents to -14 cents per share.

• Revenue rose 8.5% to $8.59 million from a year ago; analysts expected $10.55 million.

• Biofrontera Inc's reported EPS for the quarter was a loss of 47 cents​.

• The company reported a quarterly loss of $4.2 million.

• Biofrontera Inc shares had fallen by 12.6% this quarter and lost 35.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 12.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Biofrontera Inc is $10.50

This summary was machine generated from LSEG data May 15 at 09:43 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)